New Allscripts (MDRX) CFO Won't Affect M&A Potential - Analyst
Tweet
Share
E-mailGet Alerts MDRX Hot Sheet
Price: $4.26 -3.18%
Rating Summary:
8 Buy, 19 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
8 Buy, 19 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Allscripts (Nasdaq: MDRX) stock is lower Monday after announcing Richard J. Poulton will become its new CFO earlier. Some suspect that the new exec will try to stem the possibility of a merger.
One firm taking a different stance is Baird. Amid the new appointment, Baird said the potential for Allscripts to be acquired hasn't changed. In fact, Baird thinks the addition my be a modest positive for Allscipts if the firm decides to remain independent.
Allscripts recently disclosed receiving first-round bids from the likes of Carlyle, Blackstone, and others.
Shares are down 0.3 percent in afternoon trading.
One firm taking a different stance is Baird. Amid the new appointment, Baird said the potential for Allscripts to be acquired hasn't changed. In fact, Baird thinks the addition my be a modest positive for Allscipts if the firm decides to remain independent.
Allscripts recently disclosed receiving first-round bids from the likes of Carlyle, Blackstone, and others.
Shares are down 0.3 percent in afternoon trading.
Create E-mail Alert Related Categories
Analyst Comments, Management Changes, Mergers and AcquisitionsRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
